The LDLR-Mediated Neurosteroid Precursor Delivery Strategy proposes utilizing the low-density lipoprotein receptor (LDLR) not for antibody transport, but for targeted delivery of cholesterol-based neurosteroid precursors to treat neurodegenerative diseases. This approach leverages LDLR's natural affinity for apolipoprotein E (APOE)-containing lipoproteins to transport synthetic cholesterol derivatives conjugated to neuroprotective compounds across the blood-brain barrier. The mechanism involves engineering lipid nanoparticles that mimic endogenous LDL particles, incorporating APOE as a targeting ligand while carrying neurosteroid precursors such as pregnenolone or 24S-hydroxycholesterol analogs. Upon LDLR-mediated endocytosis by brain microvascular endothelial cells, these particles undergo transcytosis and release their cargo into the CNS parenchyma. The delivered neurosteroid precursors then undergo local enzymatic conversion by brain-resident steroidogenic enzymes (CYP11A1, HSD3B) to produce active neurosteroids like allopregnanolone or 24S-hydroxycholesterol metabolites.

The LDLR-Mediated Neurosteroid Precursor Delivery Strategy proposes utilizing the low-density lipoprotein receptor (LDLR) not for antibody transport, but for targeted delivery of cholesterol-based neurosteroid precursors to treat neurodegenerative diseases. This approach leverages LDLR's natural affinity for apolipoprotein E (APOE)-containing lipoproteins to transport synthetic cholesterol derivatives conjugated to neuroprotective compounds across the blood-brain barrier. The mechanism involves engineering lipid nanoparticles that mimic endogenous LDL particles, incorporating APOE as a targeting ligand while carrying neurosteroid precursors such as pregnenolone or 24S-hydroxycholesterol analogs. Upon LDLR-mediated endocytosis by brain microvascular endothelial cells, these particles undergo transcytosis and release their cargo into the CNS parenchyma. The delivered neurosteroid precursors then undergo local enzymatic conversion by brain-resident steroidogenic enzymes (CYP11A1, HSD3B) to produce active neurosteroids like allopregnanolone or 24S-hydroxycholesterol metabolites. These neurosteroids modulate GABA-A receptor function, promote oligodendrocyte survival, and enhance synaptic plasticity while reducing neuroinflammation through microglial polarization toward anti-inflammatory phenotypes. Unlike systemic neurosteroid administration, this targeted delivery bypasses peripheral metabolism and achieves therapeutic CNS concentrations while minimizing off-target effects. The strategy addresses the fundamental challenge that endogenous neurosteroid synthesis declines in aging and neurodegeneration, contributing to cognitive decline and neuronal vulnerability. By restoring local neurosteroid levels through LDLR-mediated delivery, this approach offers a physiologically-grounded therapeutic intervention for Alzheimer's disease, multiple sclerosis, and other neurodegenerative conditions where cholesterol metabolism and neurosteroid signaling are dysregulated.